Mirna

The data also indicate early signs of clinical activity in certain patients.

NEW YORK (GenomeWeb) – Researchers from Mirna Therapeutics this month published new animal data demonstrating the potential of combining two tumor-suppressing microRNA mimics for the treatment of non-small cell lung cancer (NSCLC).

Mirna Therapeutics this week announced interim data from its ongoing Phase I trial of MRX34, a microRNA mimic designed to treat cancer, which showed the drug to have a "manageable safety profile."

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

Marina Biotech and Mirna Therapeutics this week announced that they have amended an existing licensing agreement to give Mirna greater access to Marina's Smarticle liposomal delivery technology for use with microRNA-based therapeutics.

People in the News: Alan Venook, Steven Weitman
Mirna Therapeutics has appointed Alan Venook and Steven Weitman to its scientific advisory board.

Rosetta Genomics this week announced that it has been awarded a $200,000 grant along with Ramot, Tel Aviv University’s technology-transfer company, to develop microRNA-targeting cancer drugs.

People in the News: Sinil Kim

Premium

Mirna Therapeutics has named Sinil Kim as its chief medical officer.
In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.

Three months after releasing preclinical data on its microRNA replacement cancer therapy MRX34, Mirna Therapeutics has begun recruiting patients in a phase I trial of the drug, a company official said this week.

Mirna Therapeutics has appointed Clay Siegall as an outside director on its board.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.